Why Asthma Research Matters Right Now
Asthma affects roughly 25 million people in the United States, yet treatment responses vary dramatically from person to person. One patient might get full relief from a basic corticosteroid inhaler while another needs multiple medications and still ends up in the emergency room. This gap is what drives the current wave of asthma clinical trials.
The research landscape has shifted in recent years toward biologic therapies—medications that target specific inflammatory pathways rather than broadly suppressing the immune system. Drugs like omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab have already changed outcomes for many patients with severe eosinophilic or allergic asthma. Newer investigational biologics are now being tested in phase 2 and phase 3 trials across dozens of U.S. sites, with researchers looking at whether these treatments can achieve something once considered unlikely: clinical remission.
Beyond biologics, trials are also examining digital health tools that help patients manage symptoms at home, combination inhaler formulations that simplify daily routines, and interventions specifically designed for urban children with poorly controlled asthma. The American Lung Association's Airways Clinical Research Centers (ALA-ACRC) network runs multiple studies at any given time, with locations spanning from Tucson to Chicago to New York.
Types of Asthma Trials and What They Involve
Not all asthma studies are the same, and understanding the differences can help you figure out what might fit your situation.
| Trial Type | What It Tests | Typical Duration | Ideal For | Potential Benefits | Key Considerations |
|---|
| Biologic therapy trials | Injectable medications targeting specific immune pathways | 12–52 weeks | Adults with moderate-to-severe uncontrolled asthma, often with high eosinophils | Access to cutting-edge treatments; close specialist monitoring | Frequent clinic visits; possible placebo arm |
| Inhaler device studies | New formulations or delivery systems for existing medications | 8–24 weeks | Patients on ICS/LABA combinations needing better control | Simplified dosing; improved delivery | May require washout periods off current meds |
| Behavioral/digital health interventions | Apps, self-management programs, or education-based approaches | 3–12 months | Children and adults needing better daily symptom management | No medication side effects; practical skills | Requires consistent engagement with the program |
| Observational studies | No intervention—researchers track health data over time | 6 months to several years | Anyone with diagnosed asthma, mild to severe | Minimal time commitment; no treatment changes | No direct personal health benefit |
Phase 3 trials are the most common ones recruiting volunteers. These studies test treatments that have already shown promise in smaller groups and are now being evaluated in larger populations. A phase 3 trial for a new biologic, for instance, might enroll hundreds of participants across the U.S. and run for a full year. You would typically visit a study site every few weeks for lung function tests, blood work, and symptom questionnaires. Some trials also include at-home components like electronic diaries or wearable peak flow meters.
Who Can Participate and What to Expect
Eligibility requirements vary, but most asthma trials share a few common criteria. You generally need a confirmed asthma diagnosis from a physician, typically documented for at least six months to a year. Many studies specifically look for people whose asthma remains uncontrolled despite using medium-to-high dose inhaled corticosteroids. This means you might still experience symptoms more than twice a week, use a rescue inhaler frequently, or have had an exacerbation requiring oral steroids in the past year.
Age ranges differ by study. Some trials enroll children as young as two, while others focus on adults aged 18 to 80. There are also studies targeting specific populations—World Trade Center responders with certified asthma, for example, or urban children in neighborhoods with high asthma hospitalization rates. One trial currently recruiting through the ALA-ACRC network is testing whether roflumilast, a medication originally developed for COPD, can help adults with poorly controlled asthma and elevated BMI.
The screening process usually starts with a phone call or online form. A research coordinator will ask about your medical history, current medications, and recent exacerbations. If you pass this pre-screen, you will be invited for an in-person visit that includes a physical exam, spirometry testing, and a detailed review of your asthma control. You will also go through the informed consent process, where the study team explains the risks, benefits, and what participation entails before you sign anything.
Risks deserve honest attention. Any experimental treatment carries uncertainty—side effects may be unknown, and there is always a chance you will receive a placebo rather than the active drug. That said, placebo-controlled trials for asthma typically allow all participants to continue their standard rescue medications, so you are not left without any treatment. Many trials also include an open-label extension phase, meaning that after the blinded portion ends, everyone can receive the active therapy.
On the practical side, most research sites provide study-related care without billing your insurance, and compensation for time and travel is common. The amount varies; some sites offer modest per-visit payments, while others provide several hundred dollars over the course of a longer study. The Asthma and Allergy Clinical Research Center at Boston Children's Hospital, as one example, notes that compensation can reach up to $2,540 depending on the study length and visit requirements. Parking and transportation costs are often reimbursed separately. Always confirm the details with the study coordinator before enrolling.
Finding a Trial That Fits
The best starting point is ClinicalTrials.gov, where you can search by condition, location, and trial phase. Typing "asthma" and your city or state into the search bar will pull up all actively recruiting studies near you. The American Lung Association also maintains a searchable listing of trials at lung.org/research, and many academic medical centers have dedicated research pages.
If you are in the Northeast, institutions like Boston Children's Hospital, Mount Sinai in New York, and Penn Medicine in Philadelphia run multiple asthma studies year-round. The Midwest has strong programs at Northwestern in Chicago and the University of Michigan. In the South, Duke University and Baylor College of Medicine are active research hubs. The West Coast is well represented by UCSF, UCLA, and the University of Arizona in Tucson. Community-based allergy and asthma clinics also participate in multicenter trials, so you may find an option closer to home than you expect.
When you contact a study site, ask practical questions: How many visits are required, and how long does each one last? Is there an overnight stay involved? What happens if your asthma worsens during the trial? Can you continue seeing your regular doctor? The answers will help you weigh whether the commitment makes sense for your life.
Talking to your current pulmonologist or allergist is also wise. They may know about trials that suit your specific asthma subtype and can help you think through the decision. Some physicians are investigators themselves and can refer you directly.
Speaking with others who have participated can be reassuring. Sarah, a 42-year-old in Chicago, enrolled in a biologic trial after years of cycling through inhalers without relief. She described the experience as intensive—weekly visits at first, then monthly—but said the close monitoring alone was valuable. She learned more about her own asthma patterns in six months than she had in a decade of routine care. Another participant, a father in Houston whose son joined a pediatric asthma study, appreciated that the research team taught his family practical trigger-management strategies that reduced nighttime symptoms even after the trial concluded.
Asthma research is not a cure-all, and no trial guarantees improvement. But for people who feel stuck—taking their medications, avoiding triggers, and still struggling—it represents a proactive step. The treatments being studied today may become tomorrow's standard of care, and the data collected from volunteers makes that possible. If you are curious, a brief conversation with a research coordinator costs nothing and carries no obligation. You might learn something useful about your own health, even if you decide not to enroll.
研究の知恵